Meeting
2020 Genitourinary Cancers Symposium
PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC).
Authors
Robert A. Huddart
The Royal Marsden NHS Foundation Trust, Surrey, United Kingdom
Robert A. Huddart , Arlene O. Siefker-Radtke , Arjun Vasant Balar , Mehmet Asim Bilen , Thomas Powles , Aristotelis Bamias , Daniel Castellano , Maged F. Khalil , Michiel Simon Van Der Heijden , Vadim S Koshkin , David William Pook , Mustafa Ozguroglu , Linda Santiago , Rabih Saab , Pao-Chen Li , Margit Cecile Tagliaferri , Wei Lin , Mary Ann Tagliaferri , Yohann Loriot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03785925
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr TPS589)
Abstract #
TPS589
Poster Bd #
N7
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.
First Author: Arlene O. Siefker-Radtke
Poster
2022 ASCO Genitourinary Cancers Symposium
PIVOT IO 009: A phase 3, randomized study of neoadjuvant and adjuvant nivolumab (NIVO) plus bempegaldesleukin (BEMPEG; NKTR-214) versus NIVO alone versus standard of care (SOC) in patients (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin (cis)-ineligible.
First Author: Petros Grivas
Poster
2021 ASCO Annual Meeting
Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study.
First Author: Jonathan E. Rosenberg
Poster
2021 ASCO Annual Meeting
AUREA study: Atezolizumab (Atezo) combined with split-dose gemcitabine plus cisplatin (s-GC) in locally advanced or metastatic urothelial cancer (LA/mUC): A SOGUG study.
First Author: Alfonso Gomez De Liano Lista